DAWN Day One Biopharmaceuticals, Inc.
8-K Current Report
Filed: February 24, 2026
Health Care
Pharmaceutical PreparationsDay One Biopharmaceuticals, Inc. (DAWN) 8-K current report filed with SEC EDGAR on February 24, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 2.02: Results of Operations and Financial Condition
- Item 7.01: Regulation FD Disclosure
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • Q4 and full-year 2025 earnings reported Feb 24, 2026 — full results in Exhibit 99.1 press release
- • Supplemental financial presentation available in Exhibit 99.2 for deeper metrics review
Item 7.01 · Regulation FD Disclosure
- • Updated corporate presentation filed Feb 24, 2026 via Reg FD — ensures simultaneous public disclosure of material company information
- • Content of presentation not detailed in filing text — investors should review Exhibit 99.3 directly for strategic/pipeline updates
Other Day One Biopharmaceuticals, Inc. 8-K Filings
Get deeper insights on Day One Biopharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.